Eliquis Regulatory Post Marketing Surveillance

Active, not recruiting

Phase N/A Results N/A

Update History

4 Aug '17
The eligibility criteria were updated.
New
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Patients ≥19 years of age - Adult patients who are diagnosed with nonvalvular atrial fibrillation and are initiating Eliquis anticoagulation therapy for risk reduction of stroke and systemic embolism - Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study Exclusion Criteria: - Receiving Eliquis treatment for an indication that is not approved in Korea - Contraindicated for the use of Eliquis as described in the Korean label
Old
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Patients ≥19 years of age - Adult patients who are diagnosed with nonvalvular atrial fibrillation and are initiating Eliquis anticoagulation therapy for risk reduction of stroke and systemic embolism - Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study Exclusion Criteria: - Receiving Eliquis treatment for an indication that is not approved in Korea - Contraindicated for the use of Eliquis as described in the Korean label
1 Jul '17
A location was updated in Seoul.
New
The overall status was removed for Local Institution.
14 Jun '17
The gender criteria for eligibility was updated to "All."
2 Oct '14
The Summary of Purpose was updated.
New
The primary objective of this study is to examine the safety profile of Eliquis in Korean nonvalvular atrial fibrillation patients.
Old
The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the safety and effectiveness information about Eliquis in general practice
The eligibility criteria were updated.
New
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Patients ≥19 years of age - Adult patients who are diagnosed with nonvalvular atrial fibrillation and are initiating Eliquis anticoagulation therapy for risk reduction of stroke and systemic embolism - Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study Exclusion Criteria: - Receiving Eliquis treatment for an indication that is not approved in Korea - Contraindicated for the use of Eliquis as described in the Korean label
Old
Inclusion Criteria: - ≥19 years of age - Adult patients who are diagnosed with nonvalvular atrial fibrillation and are initiating Eliquis anticoagulation therapy for risk reduction of stroke and systemic embolism - Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study Exclusion Criteria: - Receiving Eliquis treatment for an indication that is not approved in Korea - Contraindicated for the use of Eliquis as described in the Korean label